Sen­ate Fi­nance chair to CMS: How can Alzheimer's pa­tients ac­cess new mAbs

Sen­ate Fi­nance Com­mit­tee Chair Ron Wyden (D-OR) sent a stern let­ter to CMS this week, call­ing on the cen­ters “to pro­vide prompt, clear, and pub­licly avail­able in­for­ma­tion” on how Medicare providers and pa­tients can par­tic­i­pate in a reg­istry or sub­mit da­ta un­der the agency’s cov­er­age with ev­i­dence de­vel­op­ment (CED) pol­i­cy that on­ly cov­ers the new amy­loid-tar­get­ed Alzheimer’s med­i­cines in cer­tain lim­it­ed cir­cum­stances.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER